Infusion-related adverse events following intravenous administration of alemtuzumab in 22 patients with MF/SS
Event . | NCI grades 1-2 patients, % . | NCI grade 3 patients, % . |
|---|---|---|
| Fever | 68 | 5 |
| Rigors | 23 | 18 |
| Nausea | 27 | 0 |
| Hypotension | 23 | 0 |
| Rash/urticaria | 14 | 0 |
| Bronchospasm | 5 | 0 |
| Fatigue | 23 | 9 |
Event . | NCI grades 1-2 patients, % . | NCI grade 3 patients, % . |
|---|---|---|
| Fever | 68 | 5 |
| Rigors | 23 | 18 |
| Nausea | 27 | 0 |
| Hypotension | 23 | 0 |
| Rash/urticaria | 14 | 0 |
| Bronchospasm | 5 | 0 |
| Fatigue | 23 | 9 |
Most side effects disappeared after 1 week during continued alemtuzumab treatment. Thirteen (59%) patients received intravenous corticosteroids as secondary prophylaxis during week 1. No grade 4 reactions occurred.